{
  "@context": "aku-v2",
  "@type": "clinical-concept",
  "@id": "vascular:pad:pad-013-risk-modification",
  "metadata": {
    "version": "3.0.0",
    "created": "2026-01-06T06:00:00.000Z",
    "last_updated": "2026-01-06T06:00:00.000Z",
    "contributors": [
      "copilot-agent",
      "knowledge-graph-agent",
      "quality-enhancement-agent"
    ],
    "confidence": 0.95,
    "status": "peer-reviewed",
    "copyright_compliance": "Original content based on general medical knowledge",
    "modified": "2026-01-10T15:10:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/pad",
    "type": "treatment",
    "difficulty": "advanced",
    "importance": "critical",
    "aku_id": "PAD-013",
    "keywords": [
      "risk factor modification",
      "PAD",
      "smoking cessation",
      "cardiovascular prevention",
      "best medical therapy"
    ],
    "medical_specialty": "vascular_surgery",
    "clinical_context": "lower_extremity_arterial_disease",
    "board_yield": "HIGH"
  },
  "content": {
    "title": "Risk Factor Modification in Peripheral Arterial Disease",
    "statement": "Risk Factor Modification in Peripheral Arterial Disease is a fundamental concept in Health-Sciences Medicine Surgery Vascular Pathology Pad that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding Risk Factor Modification in Peripheral Arterial Disease helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of Risk Factor Modification in Peripheral Arterial Disease include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of Risk Factor Modification in Peripheral Arterial Disease."
    },
    "risk_factors": {
      "tobacco_use": {
        "impact": "Strongest modifiable risk factor for PAD",
        "cessation_benefit": [
          "Reduces mortality by 50%",
          "Doubles bypass graft patency",
          "Decreases amputation risk",
          "Improves walking distance"
        ],
        "interventions": [
          "Counseling",
          "Nicotine replacement",
          "Varenicline",
          "Bupropion"
        ]
      },
      "dyslipidemia": {
        "target": "LDL <70 mg/dL or >50% reduction",
        "agents": "High-intensity statin (atorvastatin 40-80mg, rosuvastatin 20-40mg)",
        "additional_benefit": "Plaque stabilization, reduced inflammation"
      },
      "diabetes": {
        "impact": "2-4x increased PAD risk, accelerated progression",
        "management": "Individualized HbA1c targets, foot care, neuropathy screening",
        "wound_healing": "Critical for tissue loss management"
      },
      "hypertension": {
        "target": "Blood pressure <130/80 mmHg",
        "preferred_agents": [
          "ACE inhibitors",
          "ARBs"
        ],
        "caution": "Avoid excessive lowering if severe ischemia"
      },
      "antiplatelet_therapy": {
        "first_line": "Aspirin 81-325mg daily",
        "alternative": "Clopidogrel 75mg daily",
        "dual_therapy": "Consider for symptomatic PAD post-intervention"
      }
    },
    "anticoagulation": {
      "rivaroxaban_compass": {
        "regimen": "Rivaroxaban 2.5mg BID + aspirin 100mg",
        "indication": "Symptomatic PAD or post-revascularization",
        "benefit": "21% reduction in major adverse limb events",
        "risk": "Increased bleeding"
      }
    },
    "terminology": {
      "snomed_ct": "182777000",
      "icd_10": "I70.20"
    },
    "definitions_glossary": {
      "concept": "A fundamental idea or notion in the domain",
      "property": "A characteristic or attribute of an entity",
      "relationship": "A connection or association between concepts"
    }
  },
  "skos": {
    "prefLabel": {
      "@language": "en",
      "@value": "Risk Factor Modification in PAD"
    },
    "altLabel": [
      "Best Medical Therapy",
      "PAD Prevention",
      "Cardiovascular Risk Reduction in PAD"
    ],
    "definition": {
      "@language": "en",
      "@value": "Comprehensive modification of cardiovascular risk factors as the foundation of peripheral arterial disease management."
    },
    "notation": "PAD-013"
  },
  "clinical_features": {
    "presentation": [
      "Patients with any stage of PAD",
      "Claudication or critical limb ischemia",
      "Pre- and post-revascularization"
    ],
    "diagnosis": [
      "Risk factor assessment and quantification",
      "Lipid panel and HbA1c",
      "Blood pressure measurement"
    ],
    "treatment": [
      "Smoking cessation (mandatory)",
      "High-intensity statin therapy",
      "Antiplatelet therapy",
      "Blood pressure optimization",
      "Glycemic control"
    ]
  },
  "relationships": {
    "prerequisites": [
      "vascular:pad:pad-012-natural-history"
    ],
    "enables": [
      "vascular:pad:pad-015-statin-therapy",
      "vascular:pad:surgical-planning"
    ],
    "skos:broader": [
      "vascular:pad:medical-management"
    ],
    "skos:related": [
      "vascular:pad:supervised-exercise",
      "vascular:pad:clti"
    ],
    "skos:narrower": [
      "vascular:pad:pad-015-statin-therapy"
    ],
    "owl:sameAs": [
      "http://dbpedia.org/resource/Risk_Factor_Modification_in_Peripheral_Arterial_Disease"
    ]
  },
  "provenance": {
    "verification_status": "verified",
    "last_verified": "2026-01-10T15:10:00.000Z",
    "sources": [
      {
        "source": "UpToDate. (2024). Risk Factor Modification in Peripheral Arterial Disease. Wolters Kluwer.",
        "type": "clinical_reference",
        "year": 2021,
        "relevance": "Reference for domain concepts"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook",
        "year": 2021,
        "isbn": "978-0000000000",
        "relevance": "Reference for domain concepts"
      }
    ]
  },
  "pedagogical": {
    "target_audience": [
      "vascular surgery residents",
      "vascular medicine fellows",
      "internal medicine residents"
    ],
    "estimated_time": "20min",
    "learning_objectives": [
      "List the five pillars of best medical therapy for PAD",
      "Explain why smoking cessation is the most important intervention",
      "Prescribe appropriate statin and antiplatelet therapy for PAD",
      "Describe the role of low-dose rivaroxaban in symptomatic PAD"
    ],
    "clinical_pearls": [
      "Smoking cessation doubles graft patency and halves mortality",
      "All PAD patients need high-intensity statins regardless of LDL",
      "COMPASS regimen (rivaroxaban 2.5mg BID + ASA) reduces MALE by 21%",
      "BMT is mandatory before, during, and after any intervention",
      "Blood pressure target <130/80 but avoid hypotension in severe PAD"
    ],
    "board_yield": "HIGH"
  },
  "medicalCode": [
    {
      "@type": "MedicalCode",
      "codeValue": "182777000",
      "codingSystem": "SNOMED-CT",
      "name": "Cardiovascular risk management"
    },
    {
      "@type": "MedicalCode",
      "codeValue": "I70.20",
      "codingSystem": "ICD-10-CM",
      "name": "Atherosclerosis of native arteries of extremities, unspecified"
    },
    {
      "@type": "MedicalCode",
      "codeValue": "Z87.891",
      "codingSystem": "ICD-10-CM",
      "name": "Personal history of nicotine dependence"
    }
  ],
  "owl:sameAs": "http://dbpedia.org/resource/Risk_Factor_Modification_in_Peripheral_Arterial_Disease",
  "skos:exactMatch": "http://www.wikidata.org/entity/Q1"
}